home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Software Vault: The Sapphire Collection
/
Software Vault (Sapphire Collection) (Digital Impact).ISO
/
cdr16
/
med9410e.zip
/
M94B0784.TXT
< prev
next >
Wrap
Text File
|
1994-11-11
|
3KB
|
41 lines
Document 0784
DOCN M94B0784
TI Adoptive immunotherapy of cancer: a new approach for cancer treatment.
DT 9412
AU Qin YC; Limburgs Universitair Centrum, Belgium
SO Diss Abstr Int [B]; 54(6):2983 1993. Unique Identifier : AIDSLINE
ICDB/94605782
AB The conventional treatments of cancer are surgery, chemotherapy and
radiotherapy. However, the therapeutic efficacy of these treatments are
still far from satisfactory in most cases. With the development of
immunology and increasing understanding in tumor immunology,
immunotherapy has moved onto the stage of cancer treatments. Tumor
infiltrating lymphocytes (TIL) therapy, as an adoptive immunotherapy
form, has showed effectiveness in treating established lung and liver
metastases in animal models. In preliminary human trials, 55% of the
melanoma patients have responded to the TIL therapy. Studies have
demonstrated that TIL are heterogeneous containing mostly CD3+ T cells
with various amounts of CD4+ and CD8+ subsets, CD19+ B cells, CD16+ NK
cells and other mononucleocytes. Functional study of TIL revealed that
most of the T cell lines/clones derived from human breast tumor and
melanoma tissues were cytotoxic as evaluated in lectin-dependent
cytotoxicity assays which allow the detection of cytolytic T cells with
any antigen specificity. Only a small portion of cytolytic T cells
possess autologous tumor cell specificity. Analysis of T cell receptor
of TIL lines/clones regarding DNA gene rearrangement and V beta gene
expression suggest that an oligoclonal expansion of T cells might be
present in tumor sites in encountering tumor antigen(s) or tumor
associated antigen(s). The therapeutic efficacy of TIL therapy may be
enhanced by cloning autologous tumor-specific T cells from tumor
infiltrating lymphocytes, or by genetic manipulation to introduce new
functional features to the TIL. (Full text available from University
Microfilms International, Ann Arbor, MI, as Order No. AAD93-28553)
DE CD4-CD8 Ratio Clinical Trials Cytotoxicity, Immunologic Human
*Immunotherapy, Adoptive Liver Neoplasms/SECONDARY/*THERAPY Lung
Neoplasms/SECONDARY/*THERAPY Lymphocytes, Tumor-Infiltrating/IMMUNOLOGY
Melanoma/IMMUNOLOGY/PATHOLOGY Neoplasms/*THERAPY THESIS
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).